Please login to the form below

Not currently logged in
Email:
Password:

Gonal-f

This page shows the latest Gonal-f news and features for those working in and with pharma, biotech and healthcare.

Merck's pharma unit faces tougher 2017 as fertility boost recedes

Merck's pharma unit faces tougher 2017 as fertility boost recedes

company. Throughout 2016 Merck's Gonal-f fertility drug has benefited from reduced competition from Ferring's Bravelle range, which was pulled from the US market last year because of quality ... issues. In the third quarter Gonal-f grew 10% to 182m, a

Latest news

  • Merck completes €15m Spanish biotech facility expansion Merck completes €15m Spanish biotech facility expansion

    The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global ... Merck was able to raise its sales forecast for 2016 earlier

  • Fertility drugs drive healthcare growth at Merck KGaA Fertility drugs drive healthcare growth at Merck KGaA

    Fertility drugs drive healthcare growth at Merck KGaA. Strong performances from Gonal-f and Rebif boost the firm’ s 2016 sales forecast. ... In particular, the group's portfolio of fertility treatments put in a stellar performance, headed by Gonal-f

  • Roche and Merck boost manufacturing capacity Roche and Merck boost manufacturing capacity

    for a number of Merck Serono drugs, including brands such as Gonal-f (follitropin-alfa) used to treat fertility. ... Gonal-f was its fastest-growing product, with sales up 11 per cent to 152m in the quarter.

  • Sales down at Merck Serono on Rebif pressure Sales down at Merck Serono on Rebif pressure

    Among its other products, sales of Merck Serono's fertility treatment Gonal-f (follitropin alfa) slipped fractionally to 137m while growth hormone Saizen (somatropin) brought in 61m, in line with one

  • Merck KGaA to meet 2014 financial targets one year early Merck KGaA to meet 2014 financial targets one year early

    This performance helped offset declines for other key brands, such as fertility treatment Gonal-f (follitropin alfa) and growth hormone product Saizen (somatropin), down 4 and 8 per cent to 145m

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics